Fig. 2.

Time to clinical events in antithrombotic treated patients, stratified into three subgroups (DAPT, $R^{\mathrm{10}}$ and $R^{\mathrm{15}}$) according to the different antithrombotic strategy. (A) referred as the comparison between DAPT and $R^{10}$. (B) referred as the comparison between (C) DAPT and $R^{15}$. (A) Kaplan-Meier survival curve of device-related thrombus (DRT), (B) Kaplan-Meier survival curve of thromboembolic (TE) events, (C) Kaplan-Meier survival curve of bleeding events. DAPT, dual antiplatelet therapy; $R^{10}$, rivaroxaban 10 mg; $R^{15}$, rivaroxaban 15 mg; HR, hazard ratio.